PURPOSE: To evaluate the incidence of optic neuritis (ON) in patients using anti-tumor necrosis factor (TNF) alpha therapy. DESIGN: Retrospective, population-based cohort study. METHODS: We identified new users of anti-TNF therapy (etanercept, infliximab, or adalimumab) or nonbiologic disease-modifying antirheumatic drugs (DMARDs) during 2000-2007 from the following data sources: Kaiser Permanente Northern California, Pharmaceutical Assistance Contract for the Elderly, Tennessee Medicaid, and National Medicaid/Medicare. Within this cohort, we used validated algorithms to identify ON cases occurring after onset of new drug exposure. We then calculated and compared ON incidence rates between exposure groups. RESULTS: We identified 61 227 eligible inflammatory disease patients with either new anti-TNF or new nonbiologic DMARD use. Among this cohort, we found 3 ON cases among anti-TNF new users, occurring a median of 123 days (range, 37-221 days) after anti-TNF start. The crude incidence rate of ON across all disease indications among anti-TNF new users was 10.4 (95% CI 3.3-32.2) cases per 100 000 person-years. In a sensitivity analysis considering current or past anti-TNF or DMARD use, we identified a total of 6 ON cases: 3 among anti-TNF users and 3 among DMARD users. Crude ON rates were similar among anti-TNF and DMARD groups: 4.5 (95% CI 1.4-13.8) and 5.4 (95% CI 1.7-16.6) per 100 000 person-years, respectively. CONCLUSION: Optic neuritis is rare among those who initiate anti-TNF therapy and occurs with similar frequency among those with nonbiologic DMARD exposure.
PURPOSE: To evaluate the incidence of optic neuritis (ON) in patients using anti-tumor necrosis factor (TNF) alpha therapy. DESIGN: Retrospective, population-based cohort study. METHODS: We identified new users of anti-TNF therapy (etanercept, infliximab, or adalimumab) or nonbiologic disease-modifying antirheumatic drugs (DMARDs) during 2000-2007 from the following data sources: Kaiser Permanente Northern California, Pharmaceutical Assistance Contract for the Elderly, Tennessee Medicaid, and National Medicaid/Medicare. Within this cohort, we used validated algorithms to identify ON cases occurring after onset of new drug exposure. We then calculated and compared ON incidence rates between exposure groups. RESULTS: We identified 61 227 eligible inflammatory diseasepatients with either new anti-TNF or new nonbiologic DMARD use. Among this cohort, we found 3 ON cases among anti-TNF new users, occurring a median of 123 days (range, 37-221 days) after anti-TNF start. The crude incidence rate of ON across all disease indications among anti-TNF new users was 10.4 (95% CI 3.3-32.2) cases per 100 000 person-years. In a sensitivity analysis considering current or past anti-TNF or DMARD use, we identified a total of 6 ON cases: 3 among anti-TNF users and 3 among DMARD users. Crude ON rates were similar among anti-TNF and DMARD groups: 4.5 (95% CI 1.4-13.8) and 5.4 (95% CI 1.7-16.6) per 100 000 person-years, respectively. CONCLUSION:Optic neuritis is rare among those who initiate anti-TNF therapy and occurs with similar frequency among those with nonbiologic DMARD exposure.
Authors: Gabriela Schmajuk; Amal N Trivedi; Daniel H Solomon; Edward Yelin; Laura Trupin; Eliza F Chakravarty; Jinoos Yazdany Journal: JAMA Date: 2011-02-02 Impact factor: 56.272
Authors: Lisa J Herrinton; Jeffrey R Curtis; Lang Chen; Liyan Liu; Elizabeth Delzell; James D Lewis; Daniel H Solomon; Marie R Griffin; Rita Ouellet-Hellstom; Timothy Beukelman; Carlos G Grijalva; Kevin Haynes; Bindee Kuriya; Joyce Lii; Ed Mitchel; Nivedita Patkar; Jeremy Rassen; Kevin L Winthrop; Parivash Nourjah; Kenneth G Saag Journal: Pharmacoepidemiol Drug Saf Date: 2011-09-15 Impact factor: 2.890
Authors: Daniel H Solomon; Elena Massarotti; Rajesh Garg; Jun Liu; Claire Canning; Sebastian Schneeweiss Journal: JAMA Date: 2011-06-22 Impact factor: 56.272
Authors: Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Michael E Weinblatt; Soko Setoguchi; Raisa Levin; Sebastian Schneeweiss Journal: Arthritis Rheum Date: 2006-12
Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori Journal: JAMA Date: 2006-05-17 Impact factor: 56.272
Authors: Sebastian Schneeweiss; Soko Setoguchi; Michael E Weinblatt; Jeffrey N Katz; Jerry Avorn; Paul E Sax; Raisa Levin; Daniel H Solomon Journal: Arthritis Rheum Date: 2007-06
Authors: Mahsaw Motlagh; Christopher Fortenbach; Howard I Maibach; Bobeck S Modjtahedi Journal: Am J Clin Dermatol Date: 2021-11-03 Impact factor: 7.403
Authors: Lindsey B De Lott; Chun Chieh Lin; James F Burke; Beth Wallace; Daniel Saukkonen; Akbar K Waljee; Kevin A Kerber Journal: Ophthalmic Epidemiol Date: 2022-02-16
Authors: Geraldina Lionetti; Yukiko Kimura; Laura E Schanberg; Timothy Beukelman; Carol A Wallace; Norman T Ilowite; Jane Winsor; Kathleen Fox; Marc Natter; John S Sundy; Eric Brodsky; Jeffrey R Curtis; Vincent Del Gaizo; Solomon Iyasu; Angelika Jahreis; Ann Meeker-O'Connell; Barbara B Mittleman; Bernard M Murphy; Eric D Peterson; Sandra C Raymond; Soko Setoguchi; Jeffrey N Siegel; Rachel E Sobel; Daniel Solomon; Taunton R Southwood; Richard Vesely; Patience H White; Nico M Wulffraat; Christy I Sandborg Journal: Pediatrics Date: 2013-10-21 Impact factor: 7.124
Authors: Amy Kunchok; Allen J Aksamit; John M Davis; Orhun H Kantarci; B Mark Keegan; Sean J Pittock; Brian G Weinshenker; Andrew McKeon Journal: JAMA Neurol Date: 2020-08-01 Impact factor: 18.302